News

IQVIA (NYSE:IQV) Exceeds Q4 Expectations, Stock Soars

Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand, the company’s full-year revenue guidance of $15.93 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $3.12 per share was in line with analysts’ consensus estimates.